German Health Reform Law Could Shake Up Pharmaceutical Market
Executive Summary
Drug companies in the United States and Europe are warily watching a new law in Germany that could change the competitive landscape
You may also be interested in...
Pricing Experiments: Pharmas Get Creative in Germany
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: